Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions

  • Christian Uprimny
  • Alexander Stephan Kroiss
  • Clemens Decristoforo
  • Josef Fritz
  • Boris Warwitz
  • Lorenza Scarpa
  • Llanos Geraldo Roig
  • Dorota Kendler
  • Elisabeth von Guggenberg
  • Jasmin Bektic
  • Wolfgang Horninger
  • Irene Johanna Virgolini
Original Article



PET/CT with 68Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic 68Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder.


Eighty consecutive PC patients referred to 68Ga -PSMA-11 PET/CT were included in this retrospective analysis (biochemical relapse: n = 64; primary staging: n = 8; evaluation of therapy response/restaging: n = 8). In addition to whole-body PET/CT acquisition 60 min post injection early dynamic imaging of the pelvis in the first 8 min after tracer injection was performed. SUVmax of pathologic lesions was calculated and time–activity curves were generated and compared to those of urinary bladder and areas of physiologic tracer uptake.


A total of 55 lesions consistent with malignancy on 60 min whole body imaging exhibited also pathologic 68Ga-PSMA-11 uptake during early dynamic imaging (prostatic bed/prostate gland: n = 27; lymph nodes: n = 12; bone: n = 16). All pathologic lesions showed tracer uptake within the first 3 min, whereas urinary bladder activity was absent within the first 3 min of dynamic imaging in all patients. Suvmax was significantly higher in PC lesions in the first 6 min compared to urinary bladder accumulation (p < 0.001). In the subgroup of PC patients with biochemical relapse the detection rate of local recurrence could be increased from 20.3 to 29.7%.


Early dynamic imaging in 68Ga-PSMA-11 PET/CT reliably enables the differentiation of pathologic tracer uptake in PC lesions from physiologic bladder accumulation. Performance of early dynamic imaging in addition to whole body imaging 60 min after tracer injection might improve the detection rate of local recurrence in PC patients with biochemical relapse referred for 68Ga-PSMA-11 PET/CT.


Prostate cancer Biochemical recurrence 68Ga-PSMA-11 PET/CT Early dynamic imaging 

Supplementary material

259_2016_3578_MOESM1_ESM.docx (22 kb)
Supplement 1(DOCX 22 kb)
259_2016_3578_MOESM2_ESM.docx (23 kb)
Supplement 2(DOCX 22 kb)
259_2016_3578_MOESM3_ESM.docx (22 kb)
Supplement 3(DOCX 22 kb)
259_2016_3578_MOESM4_ESM.docx (22 kb)
Supplement 4(DOCX 22 kb)
259_2016_3578_MOESM5_ESM.docx (22 kb)
Supplement 5(DOCX 22 kb)
259_2016_3578_MOESM6_ESM.docx (22 kb)
Supplement 6(DOCX 22 kb)


  1. 1.
    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016. doi: 10.1016/j.eururo.2016.08.003.
  2. 2.
    Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012;188(6):2219–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2016. doi: 10.1016/j.eururo.2016.08.002.
  4. 4.
    Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int. 2004;93(5):680–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G, et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol. 2003;44(4):407–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19(3):761–9. doi:10.1007/s00330-008-1174-8.CrossRefPubMedGoogle Scholar
  7. 7.
    De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010;194(6):1427–33. doi:10.2214/AJR.10.4263. Review.CrossRefPubMedGoogle Scholar
  8. 8.
    Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59(1):51–60. doi:10.1016/j.eururo.2010.09.004.CrossRefPubMedGoogle Scholar
  9. 9.
    Simone G, Di Pierro GB, Papalia R, Sciuto R, Rea S, Ferriero M, et al. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with 18F-fluorocholine positron emission tomography/computed tomography. World J Urol. 2015;33(10):1511–8. doi:10.1007/s00345-015-1481-z.CrossRefPubMedGoogle Scholar
  10. 10.
    Evangelista L, Cimitan M, Hodolič M, Baseric T, Fettich J, Borsatti E. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. Abdom Imaging. 2015;40(8):3230–7. doi:10.1007/s00261-015-0547-0.CrossRefPubMedGoogle Scholar
  11. 11.
    Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43(1):55–69. doi:10.1007/s00259-015-3202-7.CrossRefPubMedGoogle Scholar
  12. 12.
    Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81(4):700–8. doi:10.1016/j.ejrad.2011.01.095.CrossRefPubMedGoogle Scholar
  13. 13.
    Alfarone A, Panebianco V, Schillaci O, Salciccia S, Cattarino S, Mariotti G, et al. Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol. 2012;84(1):109–21. doi:10.1016/j.critrevonc.2012.01.006.CrossRefPubMedGoogle Scholar
  14. 14.
    Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55(2):223–32. doi:10.2967/jnumed.113.123018.CrossRefPubMedGoogle Scholar
  15. 15.
    Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41(12):2222–31. doi:10.1007/s00259-014-2872-x.CrossRefPubMedGoogle Scholar
  16. 16.
    Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Zaheer A, Cho SY, Pomper MG. New agents and techniques for imaging prostate cancer. J Nucl Med. 2009;50(9):1387–90.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53(14):5333–41.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lindenberg L, Choyke P, Dahut W. Prostate cancer imaging with novel PET tracers. Curr Urol Rep. 2016;17(3):18. doi:10.1007/s11934-016-0575-5.CrossRefPubMedGoogle Scholar
  20. 20.
    Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74. doi:10.2967/jnumed.115.154153.CrossRefPubMedGoogle Scholar
  21. 21.
    Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94. doi:10.1007/s00259-015-3078-6.CrossRefPubMedGoogle Scholar
  22. 22.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. doi:10.1007/s00259-014-2949-6.CrossRefPubMedGoogle Scholar
  23. 23.
    Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6. doi:10.1007/s00259-012-2069-0.CrossRefPubMedGoogle Scholar
  24. 24.
    Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi:10.1007/s00259-013-2525-5.CrossRefPubMedGoogle Scholar
  25. 25.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90. doi:10.2967/jnumed.115.160382.CrossRefPubMedGoogle Scholar
  26. 26.
    Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611–20. doi:10.1007/s00259-016-3419-0.CrossRefPubMedGoogle Scholar
  27. 27.
    Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016;37(11):1169–79. doi:10.1097/MNM.0000000000000566.CrossRefPubMedGoogle Scholar
  28. 28.
    Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16(1):14. doi:10.1186/s40644-016-0072-6. Review.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2(1):23. doi:10.1186/2191-219X-2-23.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. doi:10.1007/s00259-012-2298-2.CrossRefPubMedGoogle Scholar
  31. 31.
    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5.Google Scholar
  32. 32.
    Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7(7):779–96.CrossRefGoogle Scholar
  33. 33.
    Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WA. Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012;23(8):1712–7. doi:10.1021/bc300103t.CrossRefPubMedGoogle Scholar
  34. 34.
    Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 Dynamic PET/CT imaging in primary prostate cancer. Clin Nucl Med. 2016;41(11):e473–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36(6):582–7. doi:10.1097/MNM.0000000000000290.CrossRefPubMedGoogle Scholar
  36. 36.
    Beheshti M, Langsteger W. PET imaging of prostate cancer using radiolabeled choline PET Clin. 2009;4(2):173–84. doi: 10.1016/j.cpet.2009.06.003.
  37. 37.
    Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009;48(1):1–9. quiz N2-3.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Christian Uprimny
    • 1
  • Alexander Stephan Kroiss
    • 1
  • Clemens Decristoforo
    • 1
  • Josef Fritz
    • 2
  • Boris Warwitz
    • 1
  • Lorenza Scarpa
    • 1
  • Llanos Geraldo Roig
    • 1
  • Dorota Kendler
    • 1
  • Elisabeth von Guggenberg
    • 1
  • Jasmin Bektic
    • 3
  • Wolfgang Horninger
    • 3
  • Irene Johanna Virgolini
    • 1
  1. 1.Department of Nuclear MedicineMedical University InnsbruckInnsbruckAustria
  2. 2.Department for Medical Statistics, Informatics and Health EconomicsMedical University InnsbruckInnsbruckAustria
  3. 3.Department of UrologyMedical University InnsbruckInnsbruckAustria

Personalised recommendations